A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults

Vaccine

Volumn 31, Issue 12, 2013, Pages 1569-1575

  Marshall, Helen S ^a   Richmond, Peter C ^b   Nissen, Michael D ^c   Wouters, Ann ^d   Baber, James ^e   Jiang, Qin ^d   Anderson, Annaliesa S ^d   Jones, Thomas R ^d   Harris, Shannon L ^d   Jansen, Kathrin U ^d   Perez, John L ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d Pfizervaccine Research   (United States)

^e PFIZER INC   (United States)

Author keywords

Bacterial outer membrane proteins; Bactericidal antibodies; Factor H binding protein; Meningococcal vaccines; Neisseria meningitidis serogroup B; Serum bactericidal assay

Indexed keywords

COMPLEMENT FACTOR H; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; NEISSERIA MENINGITIDIS SEROGROUP B BIVALENT RLP 2086 VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; CHILL; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MULTICENTER STUDY; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SERUM BACTERICIDAL TEST; YOUNG ADULT;

EID: 84875270851     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.021     Document Type: Article

References (26)

1. AUMSP. The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2010. Commun Dis Intell 2011; 35(3):217-28.
2. UK Health Protection Agency. Meningococcal Reference Unit: All laboratory confirmed cases of invasive meningococcal disease by serogroup, age and calendar year: England and Wales, 2000-2010. Available at: [accessed 19.07.12]. http://www.hpa.org.uk/web/HPAweb%26HPAwebStandard/HPAweb_C/1272032921946.
3. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10(12):853-861.
4. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27(Suppl. (2)):B51-B63.
5. Bruge J., Bouveret-Le Cam N., Danve B., Rougon G., Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004, 22(9/10):1087-1096.
6. Ishola D.A., Borrow R., Findlow H., Findlow J., Trotter C., Ramsay M.E. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin Vaccine Immunol 2012, 19(8):1126-1130.
7. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336(7659):1487-1491.
8. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24(22):4692-4700.
9. Martin D.R., Ruijne N., McCallum L., O'Hallahan J., Oster P. The VR2 epitope on the PorA P1. 7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13(4):486-491.
10. Jelfs J., Munro R., Wedege E., Caugant D.A. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 2000, 7(3):390-395.
11. Tondella M.L., Popovic T., Rosenstein N.E., Lake D.B., Carlone G.M., Mayer L.W., et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. the active bacterial core surveillance team. J Clin Microbiol 2000, 38(9):3323-3328.
12. Madico G., Welsch J.A., Lewis L.A., McNaughton A., Perlman D.H., Costello C.E., et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006, 177(1):501-510.
13. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200(3):379-389.
14. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
15. Kimura A., Toneatto D., Kleinschmidt A., Wang H., Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011, 18(3):483-486.
16. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29(7):1413-1420.
17. Richmond P.C., Nissen M.D., Marshall H.S., Lambert S.B., Roberton D., Gruber W.C., et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012, 30(43):6163-6174.
18. Marshall H.S., Richmond P.C., Nissen M.D., Jiang Q., Anderson A.S., Jansen K.U., et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial. Pediatr Infect Dis J 2012, [Epub ahead of print].
19. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28(37):6086-6093.
20. McNeil L.K., Murphy E., Zhao X.J., Guttmann S., Harris S.L., Scott A.A., et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009, 27(25-26):3417-3421.
21. Sheldon E., Schwartz H., Jiang Q., Giardina P.C. Perez JL. A Phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccine Immunother 2012, 8(7):888-895.
22. Richmond P.C., Marshall H.S., Nissen M.D., Jiang Q., Jansen K.U., Garces-Sanchez M., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12(8):597-607.
23. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(24):5093-5107.
24. Gorringe A.R., Pajon R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccine Immunother 2012, 8(2):174-183.
25. Anderson A.S., Jansen K.U., Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccine 2011, 10(5):617-634.
26. Santolaya M.E., O'Ryan M.L., Valenzuela M.T., Prado V., Vergara R., Munoz A., et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379(9816):617-624.